logo
Plus   Neg
Share
Email

Neurocrine Biosciences, Idorsia Amend Option Agreement To License ACT-709478

Neurocrine Biosciences, Inc. (NBIX) and Idorsia Ltd. have amended their 2019 agreement granting Neurocrine Biosciences an option to license ACT-709478, a potent brain penetrating T-type calcium channel blocker in development for epilepsy.

Upon Investigational New Drug application acceptance by the FDA, expected in mid-2020, Neurocrine Biosciences will have 30 days to exercise the option to license ACT-709478. If the option is exercised by Neurocrine Biosciences, Idorsia will receive an upfront payment of $45 million. Idorsia may also receive up to $365 million in additional development and regulatory milestone payments.

Also, Neurocrine Biosciences will provide an incremental $7 million in funding to Idorsia as part of the research collaboration.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The Federal Trade Commission (FTC) is in the process of sending out refund checks to consumers who were allegedly misled by Office Depot, Inc. and its software provider Support.com, Inc., into buying computer repair products and services. Out of $34 million, being the total amount of checks, Office Depot paid $25 million and Support.com paid $10 million as part of 2019 settlement. Gap Inc. partnered with fashion resale platform thredUP to facilitate the exchange of secondhand cloths. The retailer in a blog post said its customers can bring secondhand clothes in exchange for shopping credit that can be redeemed at Gap, Banana Republic, Athleta, or Janie and Jack. Customers who redeem their credits at Gap brands will receive an additional 15 percent payout bonus. Coca-Cola Co. (KO) on Friday reaffirmed its guidance for the full-year 2020 and provided an update on the expected impact from COVID-19 on first quarter 2020 results, ahead of its presentation at the Consumer Analyst Group of New York (CAGNY) Conference. For fiscal 2020, the company continues to project...
Follow RTT
>